Published in J Biol Chem on March 11, 2011
CRAC: an integrated approach to the analysis of RNA-seq reads. Genome Biol (2013) 1.26
hnRNP A1: the Swiss army knife of gene expression. Int J Mol Sci (2013) 1.19
HnRNP A1 controls a splicing regulatory circuit promoting mesenchymal-to-epithelial transition. Nucleic Acids Res (2013) 1.00
The short isoform of the CEACAM1 receptor in intestinal T cells regulates mucosal immunity and homeostasis via Tfh cell induction. Immunity (2012) 0.97
The hnRNP family: insights into their role in health and disease. Hum Genet (2016) 0.94
Crosslinking-immunoprecipitation (iCLIP) analysis reveals global regulatory roles of hnRNP L. RNA Biol (2014) 0.91
Crystal structures and RNA-binding properties of the RNA recognition motifs of heterogeneous nuclear ribonucleoprotein L: insights into its roles in alternative splicing regulation. J Biol Chem (2013) 0.91
Carcinoembryonic antigen (CEA) and its receptor hnRNP M are mediators of metastasis and the inflammatory response in the liver. Clin Exp Metastasis (2011) 0.88
Nuclear translocation of type I transforming growth factor β receptor confers a novel function in RNA processing. Mol Cell Biol (2012) 0.83
Heterogeneous Nuclear Ribonucleoprotein M Facilitates Enterovirus Infection. J Virol (2015) 0.82
Emerging roles for hnRNPs in post-transcriptional regulation: what can we learn from flies? Chromosoma (2014) 0.82
Cell cycle-regulated protein abundance changes in synchronously proliferating HeLa cells include regulation of pre-mRNA splicing proteins. PLoS One (2013) 0.81
Phosphorylation of CEACAM1 molecule by calmodulin kinase IID in a three-dimensional model of mammary gland lumen formation. J Biol Chem (2013) 0.81
Long noncoding RNA uc.345 promotes tumorigenesis of pancreatic cancer by upregulation of hnRNPL expression. Oncotarget (2016) 0.78
Novel structural co-expression analysis linking the NPM1-associated ribosomal biogenesis network to chronic myelogenous leukemia. Sci Rep (2015) 0.76
The Roles of Carcinoembryonic Antigen in Liver Metastasis and Therapeutic Approaches. Gastroenterol Res Pract (2017) 0.75
CEACAM1 as a multi-purpose target for cancer immunotherapy. Oncoimmunology (2017) 0.75
Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res (1983) 124.30
Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem (2003) 21.11
Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction. Biotechniques (1990) 13.62
ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res (2003) 12.81
Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases. Trends Biochem Sci (2000) 10.77
Pre-mRNA splicing and human disease. Genes Dev (2003) 9.13
Electrophoretic separation of complexes involved in the splicing of precursors to mRNAs. Cell (1986) 8.06
Regulation of alternative pre-mRNA splicing by hnRNP A1 and splicing factor SF2. Cell (1992) 7.90
Splicing regulation: from a parts list of regulatory elements to an integrated splicing code. RNA (2008) 6.29
RNA binding specificity of hnRNP A1: significance of hnRNP A1 high-affinity binding sites in pre-mRNA splicing. EMBO J (1994) 6.17
The role of exon sequences in splice site selection. Genes Dev (1993) 4.86
Computational definition of sequence motifs governing constitutive exon splicing. Genes Dev (2004) 4.59
Exon identity established through differential antagonism between exonic splicing silencer-bound hnRNP A1 and enhancer-bound SR proteins. Mol Cell (2001) 3.34
The MKK(3/6)-p38-signaling cascade alters the subcellular distribution of hnRNP A1 and modulates alternative splicing regulation. J Cell Biol (2000) 3.34
Mammalian heterogeneous nuclear ribonucleoprotein complex protein A1. Large-scale overproduction in Escherichia coli and cooperative binding to single-stranded nucleic acids. J Biol Chem (1988) 2.88
CEACAM1: contact-dependent control of immunity. Nat Rev Immunol (2006) 2.81
A systematic analysis of the factors that determine the strength of pre-mRNA splicing enhancers. EMBO J (1998) 2.71
Pre-mRNA splicing of IgM exons M1 and M2 is directed by a juxtaposed splicing enhancer and inhibitor. Genes Dev (1999) 2.42
hnRNP proteins and splicing control. Adv Exp Med Biol (2007) 2.39
Building specificity with nonspecific RNA-binding proteins. Nat Struct Mol Biol (2005) 2.31
Intronic CA-repeat and CA-rich elements: a new class of regulators of mammalian alternative splicing. EMBO J (2005) 2.30
Functional diversity of the hnRNPs: past, present and perspectives. Biochem J (2010) 2.29
Combinatorial control of exon recognition. J Biol Chem (2007) 2.24
The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Biochim Biophys Acta (2005) 2.15
CEACAMs: their role in physiology and pathophysiology. Curr Opin Cell Biol (2006) 2.13
hnRNP A1 relocalization to the stress granules reflects a role in the stress response. Mol Cell Biol (2006) 2.13
SR proteins and related factors in alternative splicing. Adv Exp Med Biol (2007) 2.12
hnRNP A1 selectively interacts through its Gly-rich domain with different RNA-binding proteins. J Mol Biol (1996) 2.04
CEA adhesion molecules: multifunctional proteins with signal-regulatory properties. Curr Opin Cell Biol (1997) 1.83
CEA-related antigens: molecular biology and clinical significance. Crit Rev Oncol Hematol (1985) 1.79
Protein-protein interaction among hnRNPs shuttling between nucleus and cytoplasm. J Mol Biol (2000) 1.78
CEACAM1-4S, a cell-cell adhesion molecule, mediates apoptosis and reverts mammary carcinoma cells to a normal morphogenic phenotype in a 3D culture. Proc Natl Acad Sci U S A (2003) 1.78
Small interfering RNA-mediated reduction in heterogeneous nuclear ribonucleoparticule A1/A2 proteins induces apoptosis in human cancer cells but not in normal mortal cell lines. Cancer Res (2003) 1.62
SC35 and heterogeneous nuclear ribonucleoprotein A/B proteins bind to a juxtaposed exonic splicing enhancer/exonic splicing silencer element to regulate HIV-1 tat exon 2 splicing. J Biol Chem (2003) 1.56
Alternative splicing regulation at tandem 3' splice sites. Nucleic Acids Res (2006) 1.53
hnRNP A1 and the SR proteins ASF/SF2 and SC35 have antagonistic functions in splicing of beta-tropomyosin exon 6B. J Biol Chem (2004) 1.37
Cooperative-binding and splicing-repressive properties of hnRNP A1. Mol Cell Biol (2009) 1.37
SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. Immunity (2006) 1.33
Tumor suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches. Cancer Res (1995) 1.32
Human biliary glycoprotein gene: characterization of a family of novel alternatively spliced RNAs and their expressed proteins. Mol Cell Biol (1993) 1.31
Association of pp60c-src with biliary glycoprotein (CD66a), an adhesion molecule of the carcinoembryonic antigen family downregulated in colorectal carcinomas. Oncogene (1995) 1.28
A bichromatic fluorescent reporter for cell-based screens of alternative splicing. Nucleic Acids Res (2006) 1.26
Molecular characterization of the hnRNP A2/B1 proteins: tissue-specific expression and novel isoforms. Exp Cell Res (1999) 1.25
Conserved sequence elements associated with exon skipping. Nucleic Acids Res (2003) 1.23
Heterogeneous ribonucleoprotein A1 is part of an exon-specific splice-silencing complex controlled by oncogenic signaling pathways. J Biol Chem (2000) 1.23
Heterogeneous ribonucleoprotein m is a splicing regulatory protein that can enhance or silence splicing of alternatively spliced exons. J Biol Chem (2007) 1.23
hnRNP A2 and hnRNP L bind the 3'UTR of glucose transporter 1 mRNA and exist as a complex in vivo. Biochem Biophys Res Commun (1999) 1.19
An artificial riboswitch for controlling pre-mRNA splicing. RNA (2005) 1.17
Carcinoembryonic antigen cell adhesion molecule 1 directly associates with cytoskeleton proteins actin and tropomyosin. J Biol Chem (2001) 1.13
Mutation analysis of the short cytoplasmic domain of the cell-cell adhesion molecule CEACAM1 identifies residues that orchestrate actin binding and lumen formation. J Biol Chem (2006) 1.12
Differential expression of CD66a (BGP), a cell adhesion molecule of the carcinoembryonic antigen family, in benign, premalignant, and malignant lesions of the human mammary gland. J Histochem Cytochem (1997) 1.11
Silencers regulate both constitutive and alternative splicing events in mammals. Cell Mol Life Sci (2005) 1.11
mmCGM1a: a mouse carcinoembryonic antigen gene family member, generated by alternative splicing, functions as an adhesion molecule. Cell Growth Differ (1992) 1.09
The ER repeat protein YT521-B localizes to a novel subnuclear compartment. J Cell Biol (2000) 1.08
The human tumor suppressor CEACAM1 modulates apoptosis and is implicated in early colorectal tumorigenesis. Oncogene (2004) 1.07
Antagonistic effects of the SRp30c protein and cryptic 5' splice sites on the alternative splicing of the apoptotic regulator Bcl-x. J Biol Chem (2008) 1.03
Altered splicing of CEACAM1 in breast cancer: identification of regulatory sequences that control splicing of CEACAM1 into long or short cytoplasmic domain isoforms. Mol Cancer (2008) 0.98
Biliary glycoprotein (BGPa, CD66a, CEACAM1) mediates inhibitory signals. J Leukoc Biol (2001) 0.98
Heterogeneous nuclear ribonucleoprotein A1 is identified as a potential biomarker for colorectal cancer based on differential proteomics technology. J Proteome Res (2009) 0.96
Alternative splicing: therapeutic target and tool. Prog Mol Subcell Biol (2006) 0.95
Identification of hnRNPs K, L and A2/B1 as candidate proteins involved in the nutritional regulation of mRNA splicing. Biochim Biophys Acta (2006) 0.87
Characterization of protein kinase C-mediated phosphorylation of the short cytoplasmic domain isoform of C-CAM. FEBS Lett (1998) 0.86
Carcinoembryonic antigen-stimulated THP-1 macrophages activate endothelial cells and increase cell-cell adhesion of colorectal cancer cells. Clin Exp Metastasis (2007) 0.85
Processing of carcinoembryonic antigen by Kupffer cells: recognition of a penta-peptide sequence. Arch Biochem Biophys (1996) 0.84
An exonic splicing silencer is involved in the regulated splicing of glucose 6-phosphate dehydrogenase mRNA. J Biol Chem (2006) 0.84
A network of conserved co-occurring motifs for the regulation of alternative splicing. Nucleic Acids Res (2010) 0.83
Alternative splicing as a therapeutic target for human diseases. Methods Mol Biol (2009) 0.80
Surface expression and CEA binding of hnRNP M4 protein in HT29 colon cancer cells. Anticancer Res (2005) 0.80
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature (2010) 10.09
Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res (2007) 3.37
NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw (2009) 3.25
124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med (2003) 2.44
Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res (2005) 1.88
Role for KAP1 serine 824 phosphorylation and sumoylation/desumoylation switch in regulating KAP1-mediated transcriptional repression. J Biol Chem (2007) 1.85
Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics (2011) 1.81
CEACAM1-4S, a cell-cell adhesion molecule, mediates apoptosis and reverts mammary carcinoma cells to a normal morphogenic phenotype in a 3D culture. Proc Natl Acad Sci U S A (2003) 1.78
Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. Cancer Res (2003) 1.77
Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin Cancer Res (2007) 1.75
Suppression of nonhomologous end joining repair by overexpression of HMGA2. Cancer Res (2009) 1.73
Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol (2004) 1.66
Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment. Clin Cancer Res (2010) 1.64
Pivotal advance: CEACAM1 is a negative coreceptor for the B cell receptor and promotes CD19-mediated adhesion of B cells in a PI3K-dependent manner. J Leukoc Biol (2009) 1.64
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res (2005) 1.54
A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Lett (2009) 1.49
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol (2009) 1.47
Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol (2005) 1.45
Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer. Breast Cancer Res (2009) 1.43
De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med (2012) 1.40
The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood (2008) 1.34
Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment. Oncol Rep (2006) 1.32
Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Res (2011) 1.30
The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53. Cancer Res (2003) 1.28
Defects in pre-mRNA processing as causes of and predisposition to diseases. DNA Cell Biol (2002) 1.28
Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng Des Sel (2004) 1.25
Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers. Clin Cancer Res (2011) 1.23
High plasma levels of MCP-1 and eotaxin provide evidence for an immunological basis of fibromyalgia. Exp Biol Med (Maywood) (2008) 1.21
Cell type and culture condition-dependent alternative splicing in human breast cancer cells revealed by splicing-sensitive microarrays. Cancer Res (2006) 1.21
ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway. Expert Rev Anticancer Ther (2012) 1.21
In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. Cancer Res (2004) 1.20
Development and evaluation of 18F-TTCO-Cys40-Exendin-4: a PET probe for imaging transplanted islets. J Nucl Med (2013) 1.19
Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel (2004) 1.18
High mobility group A2 potentiates genotoxic stress in part through the modulation of basal and DNA damage-dependent phosphatidylinositol 3-kinase-related protein kinase activation. Cancer Res (2005) 1.18
An artificial riboswitch for controlling pre-mRNA splicing. RNA (2005) 1.17
Down-regulation of growth arrest DNA damage-inducible gene 45beta expression is associated with human hepatocellular carcinoma. Am J Pathol (2003) 1.17
ATM-mediated serine 72 phosphorylation stabilizes ribonucleotide reductase small subunit p53R2 protein against MDM2 to DNA damage. Proc Natl Acad Sci U S A (2008) 1.17
A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Mol Cancer Ther (2006) 1.17
Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry. Am J Surg Pathol (2008) 1.16
Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis. Mol Cancer (2009) 1.14
Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET. J Nucl Med (2013) 1.14
Evidence that cathelicidin peptide LL-37 may act as a functional ligand for CXCR2 on human neutrophils. Eur J Immunol (2009) 1.14
Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother (2007) 1.13
Autoantibodies as potential biomarkers for breast cancer. Breast Cancer Res (2008) 1.13
In vivo imaging of transplanted islets with 64Cu-DO3A-VS-Cys40-Exendin-4 by targeting GLP-1 receptor. Bioconjug Chem (2011) 1.12
Human RIF1 encodes an anti-apoptotic factor required for DNA repair. Carcinogenesis (2009) 1.12
Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells. Clin Cancer Res (2006) 1.12
Mutation analysis of the short cytoplasmic domain of the cell-cell adhesion molecule CEACAM1 identifies residues that orchestrate actin binding and lumen formation. J Biol Chem (2006) 1.12
Protein phosphatase PP4 is overexpressed in human breast and lung tumors. Cell Res (2008) 1.10
Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers. Clin Sci (Lond) (2013) 1.08
Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proc Natl Acad Sci U S A (2013) 1.08
Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy. Cancer Res (2007) 1.08
Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer. Cancer Res (2011) 1.08
Hepatocarcinogenesis in FXR-/- mice mimics human HCC progression that operates through HNF1α regulation of FXR expression. Mol Endocrinol (2012) 1.08
Ligand-induced sequestering of branchpoint sequence allows conditional control of splicing. BMC Mol Biol (2008) 1.07
Ribonucleotide reductase small subunit p53R2 facilitates p21 induction of G1 arrest under UV irradiation. Cancer Res (2007) 1.07
Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma. Cancer Res (2013) 1.07
Expression of ErbB2 enhances radiation-induced NF-kappaB activation. Oncogene (2004) 1.07
A distinct metabolic signature of human colorectal cancer with prognostic potential. Clin Cancer Res (2014) 1.06
p59(fyn)-mediated phosphorylation regulates the activity of the tissue-specific splicing factor rSLM-1. Mol Cell Neurosci (2004) 1.06
Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial. Anticancer Res (2009) 1.06
Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells. Int J Cancer (2010) 1.06
Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer. Clin Colorectal Cancer (2007) 1.05
A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res (2003) 1.05
Humanization of the anti-CEA T84.66 antibody based on crystal structure data. Protein Eng Des Sel (2004) 1.05
Structurally dependent redox property of ribonucleotide reductase subunit p53R2. Cancer Res (2006) 1.04
The role of peroxiredoxin II in radiation-resistant MCF-7 breast cancer cells. Cancer Res (2005) 1.03
CEACAM1 negatively regulates IL-1β production in LPS activated neutrophils by recruiting SHP-1 to a SYK-TLR4-CEACAM1 complex. PLoS Pathog (2012) 1.03
Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments. Site-specific conjugation of DOTA-peptides to a Cys-diabody. Bioconjug Chem (2002) 1.02
Re-expression of CEACAM1 long cytoplasmic domain isoform is associated with invasion and migration of colorectal cancer. Int J Cancer (2011) 1.02
Increasing incidence of intrahepatic cholangiocarcinoma and its relationship to chronic viral hepatitis. J Natl Compr Canc Netw (2009) 1.02
Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. PLoS One (2009) 1.02
The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility. J Mol Biol (2003) 1.02
A bias-reducing strategy in profiling small RNAs using Solexa. RNA (2011) 1.02
A versatile bifunctional chelate for radiolabeling humanized anti-CEA antibody with In-111 and Cu-64 at either thiol or amino groups: PET imaging of CEA-positive tumors with whole antibodies. Bioconjug Chem (2007) 1.02
Mass spectrometry-based quantitative metabolomics revealed a distinct lipid profile in breast cancer patients. Int J Mol Sci (2013) 1.02
Symptom concerns and quality of life in hepatobiliary cancers. Oncol Nurs Forum (2008) 1.02
Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors. Cancer Lett (2011) 1.01
Direct interaction of tumor suppressor CEACAM1 with beta catenin: identification of key residues in the long cytoplasmic domain. Exp Biol Med (Maywood) (2008) 1.00
Gastric Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw (2006) 1.00
Human DNA polymerase eta activity and translocation is regulated by phosphorylation. Proc Natl Acad Sci U S A (2008) 1.00
Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models. Clin Cancer Res (2009) 1.00
Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res (2003) 1.00
2.6 A X-ray crystal structure of human p53R2, a p53-inducible ribonucleotide reductase . Biochemistry (2009) 0.99
Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth. J Control Release (2012) 0.99
p53R2 inhibits the proliferation of human cancer cells in association with cell-cycle arrest. Mol Cancer Ther (2011) 0.99
Altered splicing of CEACAM1 in breast cancer: identification of regulatory sequences that control splicing of CEACAM1 into long or short cytoplasmic domain isoforms. Mol Cancer (2008) 0.98
Role of Ceacam1 in VEGF induced vasculogenesis of murine embryonic stem cell-derived embryoid bodies in 3D culture. Exp Cell Res (2009) 0.98
MicroRNA-657 promotes tumorigenesis in hepatocellular carcinoma by targeting transducin-like enhancer protein 1 through nuclear factor kappa B pathways. Hepatology (2013) 0.98
Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin Cancer Res (2004) 0.98
Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. Hum Pathol (2005) 0.98
Carcinoembryonic antigen-related cell adhesion molecule-1 regulates granulopoiesis by inhibition of granulocyte colony-stimulating factor receptor. Immunity (2010) 0.98
Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma. Mol Cancer Ther (2005) 0.97
Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma. World J Gastroenterol (2005) 0.97
A newly identified variation at the entry of the recurrent laryngeal nerve into the larynx. J Invest Surg (2010) 0.97
The short isoform of the CEACAM1 receptor in intestinal T cells regulates mucosal immunity and homeostasis via Tfh cell induction. Immunity (2012) 0.97